研報掘金丨光大證券:維持華熙生物“買入”評級,有望借PDRN重塑輝煌
光大證券研報指出,華熙生物(688363.SH)目前已經在原料生產方面完成了破局的任務,而公司多年來在下遊功能性護膚和醫美領域積澱的豐富經驗,疊加頭部陣營的瑞吉明生物和潤輝生物的助力,華熙生物有望在未來2年,完成從原料到護膚,再到醫美產品三類證申報的三步走。而PDRN 產業的跨越式發展將爲公司帶來豐厚的利潤回報,基於此,我們繼續看好華熙生物,原料破局,應用跟進,華熙有望借PDRN重塑輝煌,維持“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.